Key Dates

Related Announcements

• September 1, 2022 - NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional). See NOFO RFA-CA-22-050.
• November 22, 2022 - Notice of Correction to RFA-CA-22-050, “NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)". See Notice NOT-CA-22-132.

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to provide clarification of eligibility for RFA-CA-22-050, “NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)". 

This clarification is aligned with the purpose stated in the funding opportunity to “increase the number of R01 Early-Stage Investigators (ESIs) and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer."

The following section of RFA-CA-22-050 has been modified to read correctly in bold italics:

Part 2. Section III. Eligibility Information

Eligible Individuals (Program Director/Principal Investigator)

• Any individual(s) with ESI status at the time of submission and the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. The following link provides more details on ESI polices and definitions. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.
• For resubmission applications, any individual(s) who revises and resubmits within 13 months of their original application will retain their ESI status (as per NIH policy) and be allowed to send in their resubmission.  In addition, any applicant that has successfully competed for an R01 or R01-equivalant award at the time of submitting the A1 resubmission no longer has ESI status and is not eligible.
• For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
• MPI applications are permissible, however, the contact PI must be an ESI with an Institutional Eligibility Letter. Visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
• The overarching goal of this program is to increase the numbers of ESIs and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer research. Fostering diversity by addressing under representation in the scientific research workforce is a key component of the NIH strategy to identify, develop, support, and maintain the quality of our scientific human capital. Despite tremendous advancements in scientific research, information, educational and research opportunities are not equally available to all. NIH encourages institutions to diversify their student, postdoctoral, and faculty populations to enhance the participation of individuals from groups identified as underrepresented in the biomedical sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIH’s Interest in Diversity), are encouraged to work with their institutions to apply for support under this program. Investigators from categories A and B are particularly encouraged to work with their institutions to apply.
• By the time of award, the PD/PI (or for a multiple PDs/PIs application, all PDs/PIs) must be a citizen or a non-citizen national of the United States or have been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status).

All other aspects of RFA-CA-22-050 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific Research Contacts

Tiffany Wallace
National Cancer Institute (NCI)
Telephone: 240-276-5114
Email: [email protected]

Eric Johnson Chavarria, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-276-7416
Email: [email protected]

Peer Review Contact(s)

Referral Officer
National Cancer Institute (NCI)
Telephone: 240-276-6390
Email: [email protected]

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute (NCI)
Telephone: 301-496-8634
Email: [email protected]